Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 281

1.

Is Lp(a) ready for prime time use in the clinic? A pros-and-cons debate.

Kostner KM, Kostner GM, Wierzbicki AS.

Atherosclerosis. 2018 Jul;274:16-22. doi: 10.1016/j.atherosclerosis.2018.04.032. Epub 2018 Apr 30. Review.

PMID:
29747086
2.

Implications of cerebrovascular ATP-binding cassette transporter G1 (ABCG1) and apolipoprotein M in cholesterol transport at the blood-brain barrier.

Kober AC, Manavalan APC, Tam-Amersdorfer C, Holmér A, Saeed A, Fanaee-Danesh E, Zandl M, Albrecher NM, Björkhem I, Kostner GM, Dahlbäck B, Panzenboeck U.

Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Jun;1862(6):573-588. doi: 10.1016/j.bbalip.2017.03.003. Epub 2017 Mar 14.

PMID:
28315462
3.

Lipoprotein (a): a historical appraisal.

Kostner KM, Kostner GM.

J Lipid Res. 2017 Jan;58(1):1-14. doi: 10.1194/jlr.R071571. Epub 2016 Nov 7. Review.

4.

MiR-206 is expressed in pancreatic islets and regulates glucokinase activity.

Vinod M, Patankar JV, Sachdev V, Frank S, Graier WF, Kratky D, Kostner GM.

Am J Physiol Endocrinol Metab. 2016 Jul 1;311(1):E175-E185. doi: 10.1152/ajpendo.00510.2015. Epub 2016 May 24.

5.

[New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk : Statement of the D•A•CH Society for Prevention of Cardiovascular Diseases, the Austrian Atherosclerosis Society and the Working Group on Lipids and Atherosclerosis (AGLA) of the Swiss Society for Cardiology].

Klose G, Beil FU, Dieplinger H, von Eckardstein A, Föger B, Gouni-Berthold I, Koenig W, Kostner GM, Landmesser U, Laufs U, Leistikow F, März W, Merkel M, Müller-Wieland D, Noll G, Parhofer KG, Paulweber B, Riesen W, Schaefer JR, Steinhagen-Thiessen E, Steinmetz A, Toplak H, Wanner C, Windler E.

Internist (Berl). 2014 May;55(5):601-6. doi: 10.1007/s00108-014-3492-z. German. Erratum in: Internist (Berl). 2014 Sep;55(9):1112.

PMID:
24770979
6.

New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk.

Klose G, Beil FU, Dieplinger H, von Eckardstein A, Föger B, Gouni-Berthold I, Heigl F, Koenig W, Kostner GM, Landmesser U, Laufs U, Leistikow F, März W, Noll G, Parhofer KG, Paulweber B, Riesen WF, Schaefer JR, Steinhagen-Thiessen E, Steinmetz A, Toplak H, Wanner C, Windler E; American Heart Association, American College of Cardiology.

Wien Klin Wochenschr. 2014 Mar;126(5-6):169-75. doi: 10.1007/s00508-014-0513-9. Epub 2014 Mar 11.

PMID:
24615676
7.

miR-206 controls LXRα expression and promotes LXR-mediated cholesterol efflux in macrophages.

Vinod M, Chennamsetty I, Colin S, Belloy L, De Paoli F, Schaider H, Graier WF, Frank S, Kratky D, Staels B, Chinetti-Gbaguidi G, Kostner GM.

Biochim Biophys Acta. 2014 Jun;1841(6):827-35. doi: 10.1016/j.bbalip.2014.02.006. Epub 2014 Mar 3.

8.

When should we measure lipoprotein (a)?

Kostner KM, März W, Kostner GM.

Eur Heart J. 2013 Nov;34(42):3268-76. doi: 10.1093/eurheartj/eht053. Epub 2013 Jun 4. Review.

PMID:
23735860
9.

Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice.

Chennamsetty I, Kostner KM, Claudel T, Vinod M, Frank S, Weiss TS, Trauner M, Kostner GM.

J Lipid Res. 2012 Nov;53(11):2405-12. doi: 10.1194/jlr.M029769. Epub 2012 Aug 28.

10.

FGF19 signaling cascade suppresses APOA gene expression.

Chennamsetty I, Claudel T, Kostner KM, Trauner M, Kostner GM.

Arterioscler Thromb Vasc Biol. 2012 May;32(5):1220-7. doi: 10.1161/ATVBAHA.111.243055. Epub 2012 Jan 19.

PMID:
22267484
11.

Expression of fat mobilizing genes in human epicardial adipose tissue.

Jaffer I, Riederer M, Shah P, Peters P, Quehenberger F, Wood A, Scharnagl H, März W, Kostner KM, Kostner GM.

Atherosclerosis. 2012 Jan;220(1):122-7. doi: 10.1016/j.atherosclerosis.2011.10.026. Epub 2011 Nov 2.

PMID:
22100250
12.

Farnesoid X receptor represses hepatic human APOA gene expression.

Chennamsetty I, Claudel T, Kostner KM, Baghdasaryan A, Kratky D, Levak-Frank S, Frank S, Gonzalez FJ, Trauner M, Kostner GM.

J Clin Invest. 2011 Sep;121(9):3724-34. doi: 10.1172/JCI45277. Epub 2011 Aug 1.

13.

Synthetic LXR agonist suppresses endogenous cholesterol biosynthesis and efficiently lowers plasma cholesterol.

Pfeifer T, Buchebner M, Chandak PG, Patankar J, Kratzer A, Obrowsky S, Rechberger GN, Kadam RS, Kompella UB, Kostner GM, Kratky D, Levak-Frank S.

Curr Pharm Biotechnol. 2011 Feb 1;12(2):285-92. Erratum in: Curr Pharm Biotechnol. 2016;17(9):846.

14.

Cholesteryl ester hydrolase activity is abolished in HSL-/- macrophages but unchanged in macrophages lacking KIAA1363.

Buchebner M, Pfeifer T, Rathke N, Chandak PG, Lass A, Schreiber R, Kratzer A, Zimmermann R, Sattler W, Koefeler H, Fröhlich E, Kostner GM, Birner-Gruenberger R, Chiang KP, Haemmerle G, Zechner R, Levak-Frank S, Cravatt B, Kratky D.

J Lipid Res. 2010 Oct;51(10):2896-908. doi: 10.1194/jlr.M004259. Epub 2010 Jul 12.

15.

Trafficking of mature miRNA-122 into the nucleus of live liver cells.

Földes-Papp Z, König K, Studier H, Bückle R, Breunig HG, Uchugonova A, Kostner GM.

Curr Pharm Biotechnol. 2009 Sep;10(6):569-78. Epub 2009 Sep 1.

PMID:
19619125
16.

Mitochondrial protein phosphorylation: instigator or target of lipotoxicity?

Graier WF, Malli R, Kostner GM.

Trends Endocrinol Metab. 2009 May;20(4):186-93. doi: 10.1016/j.tem.2009.01.004. Epub 2009 Apr 7. Review.

17.

LXR-agonists regulate ApoM expression differentially in liver and intestine.

Calayir E, Becker TM, Kratzer A, Ebner B, Panzenböck U, Stefujl J, Kostner GM.

Curr Pharm Biotechnol. 2008 Dec;9(6):516-21.

PMID:
19075690
18.

Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia.

Kratzer A, Buchebner M, Pfeifer T, Becker TM, Uray G, Miyazaki M, Miyazaki-Anzai S, Ebner B, Chandak PG, Kadam RS, Calayir E, Rathke N, Ahammer H, Radovic B, Trauner M, Hoefler G, Kompella UB, Fauler G, Levi M, Levak-Frank S, Kostner GM, Kratky D.

J Lipid Res. 2009 Feb;50(2):312-26. doi: 10.1194/jlr.M800376-JLR200. Epub 2008 Sep 23.

19.

[Fibrate in lipid metabolism disorders].

Kostner KM, Kostner GM.

Pharm Unserer Zeit. 2007;36(2):114-9. Review. German. No abstract available.

PMID:
17424996
20.

C-reactive protein, carotid atherosclerosis, and cerebral small-vessel disease: results of the Austrian Stroke Prevention Study.

Schmidt R, Schmidt H, Pichler M, Enzinger C, Petrovic K, Niederkorn K, Horner S, Ropele S, Watzinger N, Schumacher M, Berghold A, Kostner GM, Fazekas F.

Stroke. 2006 Dec;37(12):2910-6. Epub 2006 Nov 2.

PMID:
17082472
21.

Chiral separation of T3 enantiomers using stereoselective antibodies as a selector in micro-HPLC.

Koidl J, Hödl H, Schmid MG, Konrad M, Petschauer S, Kostner GM, Gübitz G.

J Biochem Biophys Methods. 2006 Nov 30;69(1-2):33-42. Epub 2006 Apr 4.

PMID:
16697467
22.

Therapy of hyper-Lp(a).

Kostner KM, Kostner GM.

Handb Exp Pharmacol. 2005;(170):519-36. Review.

PMID:
16596813
23.

A new type of non-Ca2+-buffering Apo(a)-based fluorescent indicator for intraluminal Ca2+ in the endoplasmic reticulum.

Osibow K, Malli R, Kostner GM, Graier WF.

J Biol Chem. 2006 Feb 24;281(8):5017-5025. doi: 10.1074/jbc.M508583200. Epub 2005 Dec 20.

24.

T-cadherin mediates low-density lipoprotein-initiated cell proliferation via the Ca(2+)-tyrosine kinase-Erk1/2 pathway.

Kipmen-Korgun D, Osibow K, Zoratti C, Schraml E, Greilberger J, Kostner GM, Jürgens G, Graier WF.

J Cardiovasc Pharmacol. 2005 May;45(5):418-30.

PMID:
15821437
25.

Endothelial lipase provides an alternative pathway for FFA uptake in lipoprotein lipase-deficient mouse adipose tissue.

Kratky D, Zimmermann R, Wagner EM, Strauss JG, Jin W, Kostner GM, Haemmerle G, Rader DJ, Zechner R.

J Clin Invest. 2005 Jan;115(1):161-7.

26.

Factors affecting plasma lipoprotein(a) levels: role of hormones and other nongenetic factors.

Kostner KM, Kostner GM.

Semin Vasc Med. 2004 May;4(2):211-4. Review.

PMID:
15478043
27.

Angiotensinogen promoter B-haplotype associated with cerebral small vessel disease enhances basal transcriptional activity.

Schmidt H, Aulchenko YS, Schweighofer N, Schmidt R, Frank S, Kostner GM, Ott E, van Duijn C.

Stroke. 2004 Nov;35(11):2592-7. Epub 2004 Oct 7.

PMID:
15472104
28.

[Causes of vascular injury. Endothelial function, morphology and biochemistry of atherosclerosis].

Kostner GM.

Pharm Unserer Zeit. 2003;32(6):458-63. Review. German. No abstract available. Erratum in: Pharm Unserer Zeit. 2004;33(1):27.

PMID:
14639826
29.

Defective uptake of triglyceride-associated fatty acids in adipose tissue causes the SREBP-1c-mediated induction of lipogenesis.

Wagner EM, Kratky D, Haemmerle G, Hrzenjak A, Kostner GM, Steyrer E, Zechner R.

J Lipid Res. 2004 Feb;45(2):356-65. Epub 2003 Nov 1.

30.

Galactose-specific asialoglycoprotein receptor is involved in lipoprotein (a) catabolism.

Hrzenjak A, Frank S, Wo X, Zhou Y, Van Berkel T, Kostner GM.

Biochem J. 2003 Dec 15;376(Pt 3):765-71.

31.

The Physiological Role of Lipoprotein (a).

Kostner KM, Kostner GM.

Drug News Perspect. 2002 Mar;15(2):69-77.

PMID:
12677211
32.

Human paraoxonase 1 gene polymorphisms and the risk of coronary heart disease: a community-based study.

Watzinger N, Schmidt H, Schumacher M, Schmidt R, Eber B, Fruhwald FM, Zweiker R, Kostner GM, Klein W.

Cardiology. 2002;98(3):116-22.

PMID:
12417809
33.

Endothelial cell-derived lipase mediates uptake and binding of high-density lipoprotein (HDL) particles and the selective uptake of HDL-associated cholesterol esters independent of its enzymic activity.

Strauss JG, Zimmermann R, Hrzenjak A, Zhou Y, Kratky D, Levak-Frank S, Kostner GM, Zechner R, Frank S.

Biochem J. 2002 Nov 15;368(Pt 1):69-79.

34.

Lipoprotein(a): still an enigma?

Kostner KM, Kostner GM.

Curr Opin Lipidol. 2002 Aug;13(4):391-6. Review.

PMID:
12151854
35.

Solution structure of human and bovine beta(2)-glycoprotein I revealed by small-angle X-ray scattering.

Hammel M, Kriechbaum M, Gries A, Kostner GM, Laggner P, Prassl R.

J Mol Biol. 2002 Aug 2;321(1):85-97.

PMID:
12139935
36.

Tissue-specific expression of human lipoprotein lipase in the vascular system affects vascular reactivity in transgenic mice.

Esenabhalu VE, Cerimagic M, Malli R, Osibow K, Levak-Frank S, Frieden M, Sattler W, Kostner GM, Zechner R, Graier WF.

Br J Pharmacol. 2002 Jan;135(1):143-54.

37.

Solution structure of human apolipoprotein(a) kringle IV type 6.

Maderegger B, Bermel W, Hrzenjak A, Kostner GM, Sterk H.

Biochemistry. 2002 Jan 15;41(2):660-8.

PMID:
11781107
38.

Mechanism of the interaction of beta(2)-glycoprotein I with negatively charged phospholipid membranes.

Hammel M, Schwarzenbacher R, Gries A, Kostner GM, Laggner P, Prassl R.

Biochemistry. 2001 Nov 27;40(47):14173-81.

PMID:
11714270
39.

Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis.

Caplice NM, Panetta C, Peterson TE, Kleppe LS, Mueske CS, Kostner GM, Broze GJ Jr, Simari RD.

Blood. 2001 Nov 15;98(10):2980-7.

40.

A novel splice-site mutation in intron 7 causes more severe hypercholesterolemia than a combined FH-FDB defect.

deCampo A, Schallmoser K, Schmidt H, Toplak H, Kostner GM.

Atherosclerosis. 2001 Aug;157(2):524-5. No abstract available.

PMID:
11472756
41.

Angiotensinogen polymorphism M235T, carotid atherosclerosis, and small-vessel disease-related cerebral abnormalities.

Schmidt R, Schmidt H, Fazekas F, Launer LJ, Niederkorn K, Kapeller P, Lechner A, Kostner GM.

Hypertension. 2001 Jul;38(1):110-5.

PMID:
11463770
42.

Adenovirus-mediated rescue of lipoprotein lipase-deficient mice. Lipolysis of triglyceride-rich lipoproteins is essential for high density lipoprotein maturation in mice.

Strauss JG, Frank S, Kratky D, Hämmerle G, Hrzenjak A, Knipping G, von Eckardstein A, Kostner GM, Zechner R.

J Biol Chem. 2001 Sep 28;276(39):36083-90. Epub 2001 Jun 29.

43.

Lipoprotein lipase mediates the uptake of glycated LDL in fibroblasts, endothelial cells, and macrophages.

Zimmermann R, Panzenböck U, Wintersperger A, Levak-Frank S, Graier W, Glatter O, Fritz G, Kostner GM, Zechner R.

Diabetes. 2001 Jul;50(7):1643-53.

44.

Role of various tissues in apo(a) fragmentation and excretion of fragments by the kidney.

Frank S, Hrzenjak A, Blaschitz A, Dohr G, Kostner GM.

Eur J Clin Invest. 2001 Jun;31(6):504-12.

PMID:
11422400
45.

Adenovirus-mediated apo(a)-antisense-RNA expression efficiently inhibits apo(a) synthesis in vitro and in vivo.

Frank S, Gauster M, Strauss J, Hrzenjak A, Kostner GM.

Gene Ther. 2001 Mar;8(6):425-30.

46.

Impact of apolipoprotein(a) on in vitro angiogenesis.

Schulter V, Koolwijk P, Peters E, Frank S, Hrzenjak A, Graier WF, van Hinsbergh VW, Kostner GM.

Arterioscler Thromb Vasc Biol. 2001 Mar;21(3):433-8.

PMID:
11231925
47.

Urinary excretion of apolipoprotein(a): relation to other plasma proteins.

Kostner K, Spitzauer S, Rumpold H, Maurer G, Knipping G, Hrzenjak A, Frank S, Kostner GM.

Clin Chim Acta. 2001 Feb;304(1-2):29-37.

PMID:
11165196
48.

Lipoprotein (a) up-regulates the expression of the plasminogen activator inhibitor 2 in human blood monocytes.

Buechler C, Ullrich H, Ritter M, Porsch-Oezcueruemez M, Lackner KJ, Barlage S, Friedrich SO, Kostner GM, Schmitz G.

Blood. 2001 Feb 15;97(4):981-6.

49.

Angiotensinogen gene promoter haplotype and microangiopathy-related cerebral damage: results of the Austrian Stroke Prevention Study.

Schmidt H, Fazekas F, Kostner GM, van Duijn CM, Schmidt R.

Stroke. 2001 Feb;32(2):405-12.

PMID:
11157174
50.

Apo(a)-kringle IV-type 6: expression in Escherichia coli, purification and in vitro refolding.

Hrzenjak A, Frank S, Maderegger B, Sterk H, Kostner GM.

Protein Eng. 2000 Sep;13(9):661-6.

PMID:
11054461

Supplemental Content

Loading ...
Support Center